Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 4

Astellas Pharma Inc. co-promotes telmisartan lower than the trademark Micardis®, Bayer HealthCare market telmisartan under the deride name Kinzalmono®, Kinzalkomb® (combination near hydrochlorothiazide), and Pritor® and PritorPlus® (combination with hydrochlorothiazide) inside souk across Europe. Pritor®, and PritorPlus® be also market via GlaxoSmithKline in elected markets.

The promoter of the ONTARGET® Trial Programme is Boehringer Ingelheim; co-funders in selected country be Bayer HealthCare and GlaxoSmithKline.

Boehringer Ingelheim The Boehringer Ingelheim range is one of the world's 20 former pharmaceutical guests. Headquartered in Ingelheim, Germany, it operate worldwide with 135 affiliate in 47 countries and 39,800 squad. Since it be found in 1885, the family-owned company hold be committed to research, mushrooming, sweat and marketing artistic products of big cathartic pro in support of human and veterinary pills.

In 2007, Boehringer Ingelheim post grille mart of 10.9 billion euro while outgoings one fifth of net sales in its largest firm segment Prescription Medicines over research and exciting.

Related links: Boehringer Ingelheim wring pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for Healthcare Professionals peripheral the U.S. only)Micardis® website (for Healthcare Professionals outside the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular suit in high-risk patients pitiless to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet Published online 31 August 2008.

2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.

3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high theory for vascular events. N Eng J Med 2008; 358(15):1547-59.

4. Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-coverting enzyme inhibitor psychoanalysis. A second look of the literature and pathophysiology. Ann Intern Med 1992; 117(3):234-42.

5.Matchar DB, et al. Systematic Review: Comparative usefulness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treat leading hypertension.

Ann Intern Med 2008; 148:16-29.

6. Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. US Pharmacist 2007; 32 (2).

7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. (Accessed August 2008) 8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A solid development of mortality and disability from disease, abrasion, and risk factor in 1990 and projected to 2020.

Cambridge; Harvard University Press 2001.

9. Primary Prevention of Ischemic Stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-1633.

Boehringer Ingelheim

The best medicines saw palmetto caps learn more